Drug WatchParkinson's Drug Doesn't Increase Prostate Cancer RiskAschenbrenner, Diane S. MS, RNAuthor Information Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: email@example.com. AJN, American Journal of Nursing: December 2019 - Volume 119 - Issue 12 - p 20 doi: 10.1097/01.NAJ.0000615760.33548.62 Buy Metrics Abstract The Food and Drug Administration (FDA) has determined that entacapone, used in the management of Parkinson's disease, does not increase the risk of prostate cancer or death from prostate cancer. The decision was based on an analysis of data from a postmarketing clinical trial conducted by the drug manufacturer and an FDA review of data from the Department of Veterans Affairs. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.